Mirum Pharmaceuticals Reports Strong 2025 Results, Issues Robust 2026 Sales Guidance, and Highlights Key Pipeline Catalysts
MIRM has more than doubled off its 52-week low of $36.88.
Summary
Mirum Pharmaceuticals reported strong full-year 2025 financial results, including significant product sales growth, and provided optimistic 2026 sales guidance alongside a robust pipeline update with multiple key data readouts expected.
Key Events · Earnings and Guidance · MIRM
-
Strong 2025 Financial Performance
Reported total net product sales of $521.3 million for the full year 2025, a substantial increase from $336.4 million in 2024. LIVMARLI sales grew 69% year-over-year to $360.0 million.
-
Robust 2026 Sales Guidance
Issued 2026 global net product sales guidance of $630 million to $650 million, indicating continued strong commercial growth.
-
Key Pipeline Catalysts Expected in 2026
Anticipates multiple late-stage clinical trial readouts, including Volixibat VISTAS study (PSC) topline data in Q2 2026, LIVMARLI EXPAND study topline data in Q4 2026, and Brelovitug AZURE-1 and AZURE-4 studies (HDV) topline data in H2 2026.
-
Improved Financial Position
Reduced net loss to $23.363 million for 2025 from $87.942 million in 2024, and increased unrestricted cash, cash equivalents, and investments to $391.4 million as of December 31, 2025.
Analysis · MIRM · Life Sciences
Mirum Pharmaceuticals delivered strong financial results for 2025, significantly increasing net product sales and reducing its net loss. The company's 2026 sales guidance of $630 million to $650 million indicates continued robust growth, building on the momentum from its approved products like LIVMARLI. Furthermore, the detailed pipeline update, with multiple late-stage clinical trial readouts expected throughout 2026, provides significant catalysts for future value creation in a catalyst-rich period for the company. The improved cash position also strengthens its financial flexibility.
At the time of this filing, MIRM was trading at $108.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $36.88 to $109.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.